City of Tampere: Tampere’s Hockey Hype Hits New Heights at Ice Hockey World Championship
Tampere’s target is ambitious, but understandable, considering the premium event facilities, unparalleled traditions, and a devoted city community helping Finland’s Home of Hockey in its bold aspirations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005532/en/
Brand-new Nokia Arena will be the home of 2022 IIHF Ice Hockey World Championship games played in Tampere. Europe’s most modern entertainment venue, designed by American architect Daniel Libeskind, was opened in December 2021. Photo: SRV/Libeskind/Tomorrow (Photo: Business Wire)
- This is everyone’s effort. This is the moment the whole city community has been waiting for. If there were Oscars for the event cities, our performance at 2022 IIHF Ice Hockey World Championship would win by a mile. And a half, says Perttu Pesä, the Director of Major Events at City of Tampere.
Hockey hype in Tampere is at all-time high with local teams Tappara and Ilves winning gold and bronze medals in Finnish league.
Furthermore, the games have taken place at brand-new Nokia Arena, Europe’s leading entertainment venue.
- Tampere has been a true hockey heaven throughout the spring, Atmosphere at Nokia Arena has been amazing, and we will take it to the next level together with our international friends from all over the world, says Anna-Kaisa Ikonen, Mayor of Tampere.
Tampere’s persistent work with major events, sustainability, equality, and smart city development will be the cornerstones of a successful tournament.
City offers free public transport for the game ticket holders and has provided close to 7000 tickets to specified groups, such as senior citizens and school children. Free-of-charge activity zone in the city center is open for all ages and welcomes families to try different sports activities.
Additionally, the unique smart event security solutions enable visitors to enjoy a smooth event experience during their stay.
On ice, Team Finland has a serious chance of writing history in its home tournament. After winning Olympic gold in Beijing, conquering the World Championship would make Finland the first nation to complete the double on home ice.
Free public transport: https://www.nysse.fi/en/events/ice-hockey-world-championship-2022.html
Finnish Hockey Hall of Fame: https://2022jaakiekonmmkisat.tampere.fi/en/news/renewed-hockey-hall-of-fame-finland-opened-on-april-1-2022/
Tickets for specified groups: https://2022jaakiekonmmkisat.tampere.fi/en/news/tampere-builds-ice-hockey-world-championships-for-all-citizens/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Director of Major Events
City of Tampere
+358 50 587 6200
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting26.5.2022 12:00:00 CEST | Press release
Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 (EHA2022) Congress (June 9-17; virtual and in Vienna). “We are committed to advancing science that can lead to solutions for patients with serious unmet medical needs, including those with cancer,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “For that reason, we look forward to convening with the oncology community and presenting data from across our portfolio, including both Incyte-led and partnered programs.” Key abstracts accepted by EHA include: Oral Presentation Long-term Efficacy and Safety Results from an Ongoing Open-Label Phase 2 Study of Parsaclisib for the Treatment of Autoimmune Hemolytic Anemia (AIHA) (Abstract #S286. Session: Transfusion and Autoimmune Hemolytic Anemia. Session Time: Friday, June 10, 11:30 a.m. - 12:45 p.m.) Poster Presentations A Real-World Evaluation of the Association
H.I.G. Capital Expands Its Capital Formation Middle East Team with the Addition of Oliver Slade26.5.2022 12:00:00 CEST | Press release
H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with over $49 billion of capital under management, is pleased to announce that Oliver Slade has joined the firm’s Capital Formation Group, as a Managing Director, based in Dubai. Oliver will be responsible for capital raising and investor relations activities in the Middle East. He has been based in the region since 2008 and has over 17 years of experience in alternative assets. Oliver joins H.I.G. from Partners Group, where he was the Head of Middle East and Africa, responsible for the development and capital raising activities across private markets funds and solutions in the region. Prior to Partners Group, Oliver held a similar role at GAM investments. Jordan Peer Griffin, Executive Managing Director and Global Head of Capital Formation, commented: “We are delighted to welcome Oliver to H.I.G. Given his experiences in the region, Oliver is a key addition to establish a local presence in the Middle East, wh
500 Billion Gallons of Water Prevented from Flooding Communities in 2021, Using Xylem Technology26.5.2022 12:00:00 CEST | Press release
Solutions from global water technology company Xylem (NYSE:XYL), helped prevent more than 500 billion gallons of polluted water from flooding communities in 2021, according to its annual Sustainability Report. The report highlights the Company’s work with customers and partners to solve the world’s greatest water challenges. It also details Xylem’s progress to reduce its operational footprint, including cutting Scope 1 and 2 greenhouse gas (GHG) emission intensity by 12 percent and water use by 22 percent, versus 2019. “It’s a great privilege to have a leading portfolio of technologies and services to help our customers and communities solve the water challenges so central to a more sustainable world,” said Patrick Decker, president and CEO of Xylem. “We have a responsibility to make a difference, working alongside our customers and partners, and the communities we all serve. That’s why our sustainability report is more than a set of numbers. It’s a report card on the difference we’re
SCREEN Increases Efforts to Reduce the Environmental Impact of the Semiconductor Industry26.5.2022 10:43:00 CEST | Press release
SCREEN Semiconductor Solutions Co., Ltd. (SCREEN SPE), a subsidiary of SCREEN Holdings Co., Ltd., has announced it will increase its efforts to reduce the company’s environmental overall impact. The SCREEN Group is committed to both achieving a sustainable global society and to improving its sustainable value (social value) and has formulated a medium-term management plan titled Sustainable Value 2023 targeting these goals. The plan identifies specific issues in each of the environmental, social, and governance (ESG) fields. Concerning the environment, SCREEN is working to provide products and services that actively contribute to the reduction of ecological burden. Its efforts include improving the environmental performance of its products, reducing the effects of its business activities on climate change, promoting effective utilization of water resources, increasing recycling of products and parts, and helping to preserve biodiversity. Concretely, SCREEN SPE seeks to reduce the impac
CARVYKTI ® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:10:00 CEST | Press release
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the European Commission (EC) has granted conditional marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel in December 2017. CARVYKTI® is a chimeric antigen receptor T-cell (CAR-T) therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies.1 CAR-T therapy is specifically developed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom